A study presented today at the IASLC World Conference on Lung Cancer 2022 in Vienna disclosed the clinical-relevant intertumoral heterogeneity of non-small cell lung cancer (NSCLC) driven by MET exon 14 skipping.
Aug 8, 2022
0
5
Glioblastoma multiforme (GBM) is one of the most aggressive, fast-growing tumor types, and the most common cancer of the brain with a median overall survival of approximately 15 months. Despite recent advances in treatment ...
Aug 2, 2022
0
5
Researchers at Vanderbilt University Medical Center have discovered a potential new target in the fight against colorectal cancer, the nation's third most common malignancy and, next to lung cancer, the second leading cancer ...
Jul 28, 2022
0
10
Physician-scientists at the Broad Institute of MIT and Harvard and Dana-Farber Cancer Institute have discovered that a gene called FOXR2 that is normally turned off in most tissues in the body is activated in at least 70% ...
Jul 22, 2022
0
166
Changes in DNA can lead to the development and progression of cancer. DNA serves as a template for an intermediary molecule called RNA that, in turn, codes for proteins that control all cellular processes. Most cancer research ...
Jul 14, 2022
0
92
Annual screenings of patients at high risk for lung cancer can catch tumors early and improve a patient's long-term prognosis. However, low-dose computer tomography (LDCT) has a high false-positive rate that can lead to unnecessary ...
Jul 13, 2022
0
5
Melbourne researchers have discovered that cancer and immune cells rely on the same energy sources from our body to thrive, which could trigger a fundamental rethink of treatment options for some lung cancer patients.
Jun 30, 2022
0
40
Scientists have found a way to identify and interpret 'signatures' that reveal the complex genetic causes of some of the deadliest cancers—which often have a survival rate of less than 10%. The results, published today ...
Jun 15, 2022
0
52
Nearly 43% of patients with non-small cell lung cancer (NSCLC) whose lung cancers harbored a specific KRAS mutation responded to the experimental drug adagrasib, and the targeted agent also showed activity against lesions ...
Jun 3, 2022
0
2
Mount Sinai researchers have validated for the first time that a simple blood test called a liquid biopsy could be a better predictor of whether cancer immunotherapy will be successful for a patient with lung cancer than ...
Jun 2, 2022
0
1
